NEO Neogenomics Inc

Price (delayed)

$13.85

Market cap

$1.77B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.7

Enterprise value

$2.04B

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose ...

Highlights
The company's EPS rose by 40% YoY and by 9% QoQ
The net income has grown by 39% YoY and by 9% from the previous quarter
The quick ratio has contracted by 9% YoY
The equity is down by 6% year-on-year

Key stats

What are the main financial stats of NEO
Market
Shares outstanding
127.61M
Market cap
$1.77B
Enterprise value
$2.04B
Valuations
Price to book (P/B)
1.88
Price to sales (P/S)
2.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.44
Earnings
Revenue
$591.64M
EBIT
-$90.19M
EBITDA
-$8.37M
Free cash flow
-$30.71M
Per share
EPS
-$0.7
Free cash flow per share
-$0.24
Book value per share
$7.39
Revenue per share
$4.71
TBVPS
$6.26
Balance sheet
Total assets
$1.68B
Total liabilities
$739.69M
Debt
$611.68M
Equity
$941.54M
Working capital
$500.51M
Liquidity
Debt to equity
0.65
Current ratio
6.2
Quick ratio
5.67
Net debt/EBITDA
-32.15
Margins
EBITDA margin
-1.4%
Gross margin
41.3%
Net margin
-14.9%
Operating margin
-18.2%
Efficiency
Return on assets
-5.2%
Return on equity
-9.2%
Return on invested capital
-9.1%
Return on capital employed
-5.7%
Return on sales
-15.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NEO stock price

How has the Neogenomics stock price performed over time
Intraday
0.73%
1 week
-9%
1 month
-5.72%
1 year
-9.6%
YTD
-14.4%
QTD
-11.9%

Financial performance

How have Neogenomics's revenue and profit performed over time
Revenue
$591.64M
Gross profit
$244.6M
Operating income
-$107.74M
Net income
-$87.97M
Gross margin
41.3%
Net margin
-14.9%
NEO's net margin is up by 47% YoY and by 11% QoQ
Neogenomics's operating margin has increased by 41% YoY and by 9% from the previous quarter
The net income has grown by 39% YoY and by 9% from the previous quarter
The company's operating income rose by 32% YoY and by 7% QoQ

Growth

What is Neogenomics's growth rate over time

Valuation

What is Neogenomics stock price valuation
P/E
N/A
P/B
1.88
P/S
2.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.44
The company's EPS rose by 40% YoY and by 9% QoQ
The price to book (P/B) is 51% less than the 5-year quarterly average of 3.8 and 10% less than the last 4 quarters average of 2.1
The equity is down by 6% year-on-year
The price to sales (P/S) is 55% lower than the 5-year quarterly average of 6.5 and 16% lower than the last 4 quarters average of 3.5
The revenue rose by 16% YoY and by 2.9% QoQ

Efficiency

How efficient is Neogenomics business performance
The company's return on sales rose by 49% YoY and by 20% QoQ
The return on assets rose by 36% year-on-year and by 7% since the previous quarter
NEO's ROIC is up by 35% year-on-year and by 15% since the previous quarter
The return on equity has increased by 34% year-on-year and by 7% since the previous quarter

Dividends

What is NEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NEO.

Financial health

How did Neogenomics financials performed over time
The total assets is 127% greater than the total liabilities
The quick ratio has contracted by 9% YoY
NEO's current ratio is down by 8% YoY
NEO's debt is 35% lower than its equity
The debt to equity rose by 7% year-on-year
The equity is down by 6% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.